Reversible inhibitors of SAH hydrolase and uses thereof

Details Reversible inhibitors of SAH hydrolase and uses thereof Reversible inhibitors of SAH hydrolase and uses thereof

2007-03-27

2007-03-27

Berch, Mark L. (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S263400, C514S303000, C544S276000, C544S277000, C546S116000

Reexamination Certificate

active

10410879

ABSTRACT:
1. The present invention provides compositions and methods for reversibly inhibiting S-adenosyl-L-homocysteine (SAH) hydrolase. The compounds of the present invention can be used as an anti-hemorrhagic viral infection agent, an immunosuppressant, a homocysteine lowering agent, or an anti-neoplasm agent. The compositions and methods of the present invention can be used for the prevention and treatment of hemorrhagic virus infection, autoimmune diseases, autograft rejection, neoplasm, hyperhomocysteineuria, cardiovascular disease, stroke, Alzheimer's disease, multiple sclerosis or diabetes. The compound of the present invention and/or used in the present invention has the formula (I):wherein Z is selected from the group consisting of carbon and nitrogen,R1 and R2 are the same or different, and are selected from the group consisting of hydrogen, hydroxy, alkyl, cycloalkyl, alkenyl, alkoxy, amino, aryl, heteroaryl, and halogen;R3 and R4 are the same or different and are selected from the group consisting of hydrogen, alkyl, acetyl, alkenyl, aryl, and heteroaryl;X is selected from the group consisting of oxygen, nitrogen, and sulfur; andY is selected from the group consisting of hydrogen, a C1-10alkyl group, alkenyl, vinyl, aryl, and heteroaryl, provided that the compound is not (4-adenine-9-yl)-2-hydroxybutanoic acid.

REFERENCES:
patent: 5593990 (1997-01-01), D'Amato
patent: 5629327 (1997-05-01), D'Amato
patent: 5641783 (1997-06-01), Klein et al.
patent: 5668173 (1997-09-01), Garrow
patent: 5686102 (1997-11-01), Gross et al.
patent: 5712291 (1998-01-01), D'Amato
patent: 5736154 (1998-04-01), Fuisz
patent: 5741511 (1998-04-01), Lee et al.
patent: 5756466 (1998-05-01), Bemis et al.
patent: 5854023 (1998-12-01), Hillman et al.
patent: 5869305 (1999-02-01), Samulski et al.
patent: 5886039 (1999-03-01), Kock et al.
patent: 5888767 (1999-03-01), Dropulić et al.
patent: 5941868 (1999-08-01), Kaplan et al.
patent: 5962274 (1999-10-01), Parks
patent: 6020337 (2000-02-01), Leigh et al.
patent: 6066467 (2000-05-01), Xu et al.
patent: 6133274 (2000-10-01), Underiner et al.
patent: 6197801 (2001-03-01), Lin
patent: 6203818 (2001-03-01), Vester
patent: 6210686 (2001-04-01), Bell et al.
patent: 6258374 (2001-07-01), Friess et al.
patent: 6274170 (2001-08-01), Heibel et al.
patent: 6323188 (2001-11-01), Weissman
patent: 6353003 (2002-03-01), Anderson
patent: 6361800 (2002-03-01), Cooper et al.
patent: 2002/0044919 (2002-04-01), Yu
patent: 2005/0182075 (2005-08-01), Yuan
patent: 1330704 (1773-09-01), None
patent: 1330704 (1973-09-01), None
Hana Dvorakova, et al., Collection of Czechoslovak Chemical Communications 1993, 58(3), 629-648.
Autoimmunity, Methods and Protocols, Chapter 19, pp. 365-375 in Methods in Molecular Medicine, vol. 102, Ed. by A. Perl , Human Press, 2004.
't Hart et al. Drug Discovery Today 9: 517-524 (2004).
Dictionary of Biochemistry and Molecular Biology, Second Ed., (John Wiley & Sons, 1989) p. 417.
Association of the British Pharmaceutical Industry, “Target Crohn's and Colitis: Inflammatory Bowel Disease and the Pharmaceutical Industry- Future Medicines in the Development Pipeline” at <http://www.abpi.org.uk> (visited Feb. 4, 2003).
Auerbach and Auerbach, “Angiogenesis Inhibition: A Review” Pharmacol. Ther. 63:265-311 (1994).
Bao, L. et al., “The Critical Role of IL-12p40 in Initiating, Enhancing, and Perpetuating Pathogenic Events in Murine Experimental Autoimmune Neuritis” [Abstract] at <http://www.brainpathology.com> (visited Feb. 4, 2003).
Bartlett et al., “CAVEAT: A Program to Facilitate the Structure-Derived Design of Biologically Active Molecules”In Molecular Recognition in Chemical and Biological Problems, Special Pub., Royal Chem. Soc. 78:182-196 (1989).
Bohm, “The Computer Program LUDI: A New Method for the De Novo Design of Enzyme Inhibitors” J. Comp. Aid. Molec. Design 6:61-78 (1992).
Brooks et al., “CHARMM: A Program for Macromolecular Energy, Minimization, and Dynamics Calculations” J Comp. Chem. 4(2):187-217 (1983).
Cerino, V., “UNMC Dentistry Researchers Receive $209,000 Grant to Study Role of Protein in Multiple Sclerosis” at <http://www.unmc.edu/News/petro.htm> (visited Feb. 4, 2003).
Chem. Abstr. 1972:514811 (Abstract to JP47-023550).
Cohen et al., J. Med. Chem. 33:883-894 (1990).
Commission of Biochemical Nomenclature, “IUPAC-IUB Commission on Biochemical Nomenclature Symbols for Amino-Acid Derivatives and Peptides Recommendations (1971)” Biochemistry 11:1726-1732 (1972).
Coulter-Karis and Hershfield, “Sequence of Full Length cDNA for Human S-Adenosylhomocysteine Hydrolase” Ann. Hum. Genet. 53(2):169-175 (1989).
Gewolb, J., “New Diabetes Gene Found” at <http://bric.postech.ac.kr/science/97now/01—1now/010130a.html> (visited Feb. 4, 2003).
Goodford, “A Computational Procedure for Determining Energetically Favorable Binding Sites on Biologically Important Macromolecules” J. Med. Chem. 28:849-857 (1985).
Goodman and Gilman,The Pharmacological Basis of Therapeutics, (9thed.), McGraw-Hill pp. 1294-1304 (1996).
Goodsell et al., “Automated Docking of Substrates to Proteins by Simulated Annealing” Proteins: Structure, Function and Genetics 8:195-202 (1990).
Holy et al., “Structure-Activity Studies on Open-Chain Analogues of Nucleosides: Inhibition of S-Adenosyl-L-Homocysteine Hydrolase and Antiviral Activity” Coll. Czechoslovak Chem. Commun. 50:262-279 (1985).
Holy, Coll. Czech. Chem. Commun. 43:3444-3464 (1978).
Hopfinger et al.,In Concepts and Applications of Molecular SimilarityJohnson and Maggiora (eds.), Wiley (1990).
Kirkman, R., “Protein Design Labs (PDLI) Begins Phase I Clinical Trial of SMART Anti-IL-12 Antibody” at <http://www.biospace.com
ews—story.cfm?storyID=9223720&full=1> (visited Feb. 4, 2003).
Klebe, G., “Recent Developments in Structure-Based Drug Design” J. Mol. Med. 78:269-281 (2000).
Kuntz et al., “A Geometric Approach to Macromolecule-Ligand Interactions” J. Mol. Biol. 161:269-288 (1982).
Maignan et al., Curr. Top. Med. Chem. 1:161-174 (2001).
Marshall, Ann. Ref. Pharmacol. Toxicol. 27:193 (1987).
Martin, “3D Database Searching in Drug Design” J. Med. Chem. 35(12):2145-2154 (1992).
Mayer et al., J. Comp. Aided Molec. Design 1:3-16 (1987).
Merta, A. et al., “S-Adensoyl-L-Homocysteine Hydrolase from Mouse Leukemic Cells: Isolation and Properties” Coll. Czech. Chem. Commun. 48:2701-2708 (1983).
Miranker et al., “Functionality Maps of Binding Sites: A Multiple Copy Simultaneous Search Method” Proteins: Structure, Function and Genetics 11:29-34 (1991).
National Institute of Health, “Understanding Autoimmune Disease” at <http://www.niaid.nih.gov/publications/autoimmune/autoimmune.htm> (visited Apr. 10, 2003).
Navia et al., Curr. Opin. Struc. Biol. 2:202-210 (1991).
Nishibata et al., “Automatic Creation of Drug Candidate Structures Based on Receptor Structure. Starting Point for Artificial Lead Generation” Tetrahedron 47(43):8985-8990 (1991).
O'Reilly, M., “The Preclinical Evaluation of Angiogenesis Inhibitors” Investigational New Drugs 15:5-13 (1997).
Schanche, et al., “The Effect of Aliphatic Adenine Analogues on S-Adenosylhomocysteine and S-Adenosylhomocysteine Hydrolase in Intact Rat Hepatocytes” Molecular Pharmacology 26:553-558 (1984).
Seshadri et al., “Plasma Homocysteine As a Risk Factor for Dementia and Alzheimer's Disease” N. Eng. J. Med. 46:476-483 (2002).
Simpson et al., “Spectrophotometric Determination of Lymphocyte Mediated Sheep Red Blood Cell Hemolysis In Vitro” J. Immunol. Methods 21:159-165 (1978).
Steinman, L., “Multiple Sclerosis: A Two-Stage Disease” 2001 Nature Publishing Group http://immunol.nature.com.
Votruba and Holy, “Eritadenines- Novel Type of Potent Inhibitors of S

Affiliated with

Also associated with

Rating

Reversible inhibitors of SAH hydrolase and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Reversible inhibitors of SAH hydrolase and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Reversible inhibitors of SAH hydrolase and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3765815